Natco Pharma Launches Generic Pomalidomide for Blood Cancer Treatment in US
Natco Pharma
Natco Pharma has announced the launch of Pomalidomide capsules in the United States market, in partnership with Breckenridge Pharmaceutical, Inc. The drug is indicated for the treatment of adult patients suffering from specific blood and bone marrow cancers.
Pomalidomide capsules are the generic equivalent of Pomalyst, originally developed by Celgene. The medication is being made available in 1mg, 2mg, 3mg, and 4mg strengths and will primarily be distributed through specialty pharmacies and clinical channels, according to a regulatory filing by the company.
Commenting on the development, Vice Chairman and CEO Rajeev Nannapaneni said,"...this further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide."
He further said,"We look forward to bringing more such complex and specialty products to the market in the coming years."
Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc, said,"Breckenridge's launch of Pomalidomide capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care."
Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc, said,"Breckenridge's launch of Pomalidomide capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care."
He added that access and affordability remain significant concerns for patients reliant on specialty therapies.
Natco Pharma stated that Pomalidomide capsules are indicated for adult patients with multiple myeloma who have undergone at least two prior treatments, including lenalidomide and a proteasome inhibitor, and have experienced disease progression during or within 60 days of completing the last therapy. The drug is also approved for the treatment of AIDS-related Kaposi sarcoma following failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients diagnosed with Kaposi sarcoma.
Natco Pharma stated that Pomalidomide capsules are indicated for adult patients with multiple myeloma who have undergone at least two prior treatments, including lenalidomide and a proteasome inhibitor, and have experienced disease progression during or within 60 days of completing the last therapy. The drug is also approved for the treatment of AIDS-related Kaposi sarcoma following failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients diagnosed with Kaposi sarcoma.
According to industry sales data, Pomalidomide capsules in the 1mg to 4mg strengths recorded estimated sales of USD 3.2 billion in the United States for the 12-month period ending September 2025.
Natco further stated that, based on information provided by the US Food and Drug Administration (FDA), it has been granted 180 days of shared marketing exclusivity for the drug.
Natco further stated that, based on information provided by the US Food and Drug Administration (FDA), it has been granted 180 days of shared marketing exclusivity for the drug.
